Lorcaserin in Obesity: Identification of CNS Targets Using FMRI

NCT ID: NCT02400359

Last Updated: 2025-03-21

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2026-03-31

Brief Summary

The purpose of this protocol is to investigate, using functional magnetic resonance imaging (fMRI), the effect of treatment with lorcaserin on centers of the brain that control appetite and food intake, as well as lorcaserin's downstream metabolic effects.

Detailed Description

The purpose of this protocol is to investigate the effect of treatment with the study drug, called lorcaserin on centers of the brain that control appetite and food intake, as well as lorcaserin's other metabolic effects. Lorcaserin's effect on the brain will be investigated using functional magnetic resonance imaging (fMRI). Lorcaserin was approved in June 2012 as an addition to a reduced-calorie diet and exercise, for chronic weight management. Previous weight loss drugs, such as fenfluramine, acted throughout the body and caused heart problems. Lorcaserin is different because it only acts on receptors (sites of action) that are found in the brain and does not act on the heart, and thus, has not been shown to cause the heart problems seen in the past.

1. To examine the effects of the study drug lorcaserin, on the brain, and its impact on food visualization (high fat and low fat images) and interaction with satiety (by measuring during the fasting or fed states) using fMRI. (Satiety is defined as when a person has had enough or too much food and does not want to eat any more, as after finishing a satisfying meal.)

2. To examine the satiety and weight-reducing effect of lorcaserin using physiological measurements (such as how much weight is lost and how this may affect hormone levels), and its association with changes in fMRI responses and neuropsychological performance. To examine whether the long-term weight reducing effects of lorcaserin can be predicted by early food visualization.

Conditions

Obesity; Weight Loss

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Subjects will be randomized to either placebo or Lorcaserin HCl.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.

Active

Subjects will be randomized to either placebo or Lorcaserin HCl.

Group Type: ACTIVE_COMPARATOR

Lorcaserin HCl

Intervention Type: DRUG

Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.

Interventions

Lorcaserin HCl

Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.

Intervention Type: DRUG

Placebo

This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.

Intervention Type: DRUG

Other Intervention Names

Belviq

Eligibility Criteria

Inclusion Criteria

Obese: BMI> 30 kg/m2 or >27 kg/m2 with comorbidities (including but not limited to insulin resistance, hypertension, dyslipidemia, cardiovascular disease, stroke, sleep apnea, gallbladder disease, hyperuricemia and gout, and osteoarthritis).

Additionally, women participants must use double barrier methods to prevent pregnancy (diaphragm with intravaginal spermicide, cervical cap, male or female condom with spermicide). If a woman suspects that she has become pregnant at any time or does not use one of the contraceptive methods recommended by the investigator, she must notify the study staff. If a woman becomes pregnant, she will be withdrawn from the study. The study staff will follow the progress of her pregnancy and the birth of her child.

Exclusion Criteria

1. Subjects using any other weight loss products (orlistat, phentermine, topiramate, fenfluramine, dexfenfluramine, amphetamines, GLP-1 agonists) or use within 3 months.

2. Women who are breastfeeding, pregnant, or wanting to become pregnant.

3. Women using IUD (intrauterine device)

4. Any change in the dosage of hormonal contraceptive medications (birth control pills, implanon). Subjects should remain on same medication/ same dose during the time of the entire study.

5. Moderate (creatinine clearance of 30-59 ml/min) and severe renal impairment (creatinine clearance below 30 ml/min) and end-stage renal disease

6. Moderate, or severe hepatic impairment

7. Hypersensitivity to the active substance or any of the excipients in lorcaserin

8. Congestive heart failure and/or pulmonary hypertension

9. Arrhythmias (bradycardia, tachycardia) and valvular heart diseases

10. Diagnosis of diabetes, defined per ADA criteria as Hba1c > 6.5% and/or fasting glucose > 125 mg/dL and/or random glucose > 200 mg/dL

11. Inflammatory conditions like inflammatory bowel disease, Rheumatoid arthritis etc.

12. Alcohol consumption- the maximum quantity for men is 140g-210g per week. For women, the range is 84g-140g per week or drinking as consuming no more than two drinks a day for men and one for women. Alcohol can cause increased risk of pancreatitis and hypoglycemia.

13. Untreated thyroid disease like hypothyroidism or hyperthyroidism

14. Subjects taking the following medications: phosphodiesterase inhibitors, serotonergic medications (e.g. SSRI (selective serotonin reuptake inhibitor), SNRI, MAO (monoamine oxidase) inhibitors, bupropion, tricyclic antidepressants, St. John's Wort), valproic acid, codeine (CYP2D6 inhibition), tamoxifen, timolol, warfarin, steroids (inhaled or systemic due to reduced hypoglycemic effect), and subjects on other hormones (LHRH analogs etc).

15. Subjects with any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g. cochlear implants, pacemakers, neuron or biostimulators, electronic infusion pumps, etc.)

16. Subjects with any type of metallic implant that could potentially be displaced or damaged during MRI, such as aneurysm clips, metallic skull plates, surgical implants etc. or metal containing tattoos

17. Anxiety of small spaces and/or claustrophobia

18. Uncontrolled cardiac impairment, circulatory impairment, or inability to perspire (poor thermoregulatory function)

19. Significant sensory or motor impairment

20. Epilepsy, particularly photo-sensitive epilepsy, which may place the individual at a higher risk for adverse events during fMRI scanning with visual stimulation

21. Subjects with neurological problems which may interfere with or complicate testing (e.g. presence of titubation)

22. Body weight above the limitation of the MRI scanning table (330lbs/150 Kg) or body dimensions that could difficult the performance of the scan.

23. Subjects who cannot adhere to the experimental protocol for any reason

24. Anemia with Hgb less than 10

25. Uncontrolled infectious diseases (e.g. HIV, hepatitis, chronic infections etc)

26. Any uncontrolled endocrine condition, e.g. Cushing's, Acromegaly, etc

27. Any cancers or lymphoma

28. Eating disorders like anorexia, bulimia

29. Weight loss surgery or gastrectomy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Beth Israel Deaconess Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Christos Mantzoros

Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Christos S Mantzoros, MD DSc

Role: PRINCIPAL_INVESTIGATOR

Beth Israel Deaconess Medical Center

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Countries

United States

References

Farr OM, Upadhyay J, Gavrieli A, Camp M, Spyrou N, Kaye H, Mathew H, Vamvini M, Koniaris A, Kilim H, Srnka A, Migdal A, Mantzoros CS. Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Diabetes. 2016 Oct;65(10):2943-53. doi: 10.2337/db16-0635. Epub 2016 Jul 6.

Reference Type: DERIVED

PMID: 27385157 (View on PubMed)

Other Identifiers

2014P000196

Identifier Type: -

Identifier Source: org_study_id